CAMBRIDGE, Mass. – March 28, 2026 – Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled software-as-a-medical-device (SaMD) that detects early signs of PH, a serious and progressive condition affecting the lungs and right side of the heart. The algorithm, which previously received FDA Breakthrough Device Designation, is the first PH algorithm cleared for use with standard 12-lead electrocardiograms (ECGs), making it broadly accessible across care settings.
PH is a progressive, life-threatening pulmonary vascular disease estimated to affect up to 1% of the global population.1 It is often difficult to diagnose2 due to non-specific early symptoms, such as dyspnea, with delays frequently exceeding two years.3 These delays are associated with increased morbidity and mortality, highlighting the need for earlier detection.4 Anumana’s algorithm enhances the standard 12-lead ECG by detecting subtle abnormalities that may not be visible to the human eye, helping clinicians identify when follow-up testing, such as echocardiography, is warranted using existing clinical workflows.
“Pulmonary hypertension is often difficult to recognize until it has progressed significantly, leaving patients and physicians at a disadvantage,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and a member of the Anumana advisory board. “FDA clearance of Anumana’s PH algorithm provides clinicians with a practical solution to identify PH earlier and determine appropriate next steps in care, expanding the clinical utility of routine ECGs.”
The PH algorithm helps clinicians identify subtle patterns associated with early PH in standard 12-lead ECGs. It integrates with EHR systems, including ECG management platforms, and runs entirely within the health system environment without transferring patient data.
“The FDA clearance of our Pulmonary Hypertension algorithm is the result of rigorous clinical development and regulatory work, and it marks a meaningful step toward expanding access to AI-enabled insights at the point of care,” said Simos Kedikoglou, President & COO of Anumana. “As the first PH algorithm cleared for use with standard 12-lead ECGs, it is broadly accessible across care settings, integrates directly into existing clinical workflows, and supports clinical decision-making in real time, with the potential to help identify patients earlier in their disease course. This milestone reflects Anumana’s broader vision to expand the role of ECGs in identifying cardiovascular risk earlier and at scale.”
With this clearance, Anumana continues to broaden its portfolio of AI-enabled, workflow-integrated solutions. The company is demonstrating clear leadership in advancing clinically validated solutions across geographies, delivering detectable, reliable insights to clinicians and patients in diverse care settings worldwide.
Anumana’s ECG-AI PH algorithm was developed using over 250,000 de-identified patient records from Mayo Clinic.5 In an independent, multi-center study of 21,066 patients across five U.S. health systems, ECG-AI detected PH with 73% sensitivity and 74.4% specificity in adult patients presenting with dyspnea. In a separate real-world analysis study of patients with an ECG available between symptom onset and PH diagnosis, ECG-AI identified more than 85% of patients with pulmonary arterial hypertension (PAH) and 78% with chronic thromboembolic pulmonary hypertension (CTEPH).6 This suggests a potential opportunity to support earlier detection of these two treatable PH subgroups.
Mayo Clinic co-founded Anumana and has a financial interest in the company.
About Anumana
Anumana is an AI-driven health technology company committed to transforming cardiovascular care. Co-founded by nference and Mayo Clinic, Anumana develops software-as-a-medical-device (SaMD) solutions that apply multimodal AI to support early detection, clinical decision-making, and intraoperative guidance across the continuum of care. The company’s portfolio includes ECG-based algorithms, generative imaging applications, and real-time procedural support tools designed to improve outcomes in both diagnostic and intraoperative settings. The company’s FDA-cleared ECG-AI™ LEF and ECG-AI™ PH algorithms are currently available in the U.S. and eligible for reimbursement. To learn more or schedule a demo, visit ECG-AI LEF. Please visit www.anumana.ai for more information and follow Anumana on LinkedIn and X for company updates.
###
Media Contact
Andrea Sampson
President/CEO, Sampson Public Relations Group
asampson@sampsonprgroup.com
References
- Ley L, Grimminger F, Richter M, Tello K, Ghofrani A, Bandorski D. The Early Detection of Pulmonary Hypertension. Dtsch Arztebl Int. 2023;120(48):823-830. doi:10.3238/arztebl.m2023.0222.
- Dardi F, McCullagh B, Madureira Antunes Ferreira F, Meandzija M, Neill W, Cruz-Utrilla A. Delays in the diagnosis and management of pulmonary arterial hypertension: A simulated patient cases study across four European countries. ERJ Open Research. 2026:01693-02025. doi:10.1183/23120541.01693-2025.
- DuBrock HM, Silvert E, Doddahonnaiah D, et al. Assessing the Impact of Time to Diagnosis and Treatment for Patients With Pulmonary Arterial Hypertension. Pulm Circ. 2025;15(4):e70208. Published 2025 Dec 15. doi:10.1002/pul2.70208.
- Kubota K, Miyanaga S, Akao M, et al. Association of delayed diagnosis of pulmonary arterial hypertension with its prognosis. Journal of Cardiology. 2024;83(6):365-370. doi:10.1016/j.jjcc.2023.08.004.
- DuBrock HM, Wagner TE, Carlson K, et al. An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension. Eur Respir J. 2024;64(1):2400192. Published 2024 Jul 25. doi:10.1183/13993003.00192-2024.
- Anumana data on file.